Please note that Gilead Medical Information will forward the reports to our Drug Safety and Public Health Department, which in certain circumstances may contact you for more information about a report.
Gilead Sciences Ltd consistently collates and reviews product safety information received from clinical trials and post-marketing activities. The information received is evaluated on an on-going basis ensuring the continuous surveillance of Gilead Sciences Ltd products.
Date of preparation: June 2019
This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.